PleoPharma Introduces Innovative Data on Cannabis Withdrawal and Phase 2 PP-01 Outcomes

PleoPharma Presents Groundbreaking Research on Cannabis Withdrawal

PleoPharma, a company dedicated to clinical research in cannabis-related health issues, is poised to showcase new findings on cannabis withdrawal at the upcoming 88th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD). This significant event will take place from June 13 to June 17, 2026, in Portland, Oregon, and PleoPharma’s presentations are scheduled for June 15.

Understanding Cannabis Withdrawal and Use Disorder

One of the key presentations will focus on the experiences of patients grappling with cannabis withdrawal syndrome associated with Cannabis Use Disorder (CUD). Current treatment options are severely limited, with no FDA-approved therapies available for those suffering from withdrawal symptoms. PleoPharma aims to fill this glaring gap in medical treatment through its innovative findings.

Comprehensive Patient-Centric Research

The first poster details a qualitative study that provides crucial insights into the severity and onset of withdrawal symptoms from cannabis. Dr. Ashley Slagle, Chief Clinical Outcome Officer at PleoPharma, emphasized the importance of understanding the patient perspective, stating, "These findings shed light on the significant burden withdrawal imposes, emphasizing the need for more effective treatment pathways."

This study involved 15 adults and analyzed the impact of withdrawal symptoms, indicating the challenges faced by individuals seeking to reduce or cease cannabis use.

Promising Phase 2 Trial Results for PP-01

The second presentation will provide preliminary data from the Phase 2 CAN-002 clinical trial for PP-01, a once-daily oral treatment aimed at alleviating withdrawal symptoms in patients with CUD. The trial results indicate a noteworthy 43% reduction in irritability symptoms compared to a placebo, particularly during the critical withdrawal days of 2-5.

Dr. Ginger Constantine, CEO of PleoPharma, remarked on the significance of these findings: "The CAN-002 results add weight to the evidence supporting the potential of PP-01 in treating withdrawal symptoms. We’re eager to share these insights with experts at CPDD, reaffirming our commitment to addressing unmet medical needs in this area."

The Future of Cannabis Treatment

PP-01 operates on a dual mechanism targeting suppressed CB1 receptors involved in cannabis addiction. The research underscores its potential as a first-in-class treatment, designed to improve rapid onset of action, safety, and patient tolerability.

PleoPharma's journey reflects a dedicated effort towards developing effective interventions for individuals suffering from cannabis addiction and related health issues. With a management team renowned for its clinical success and numerous product approvals worldwide, PleoPharma is positioning itself at the forefront of cannabis research.

As PleoPharma prepares for their presentations at the CPDD, the cannabis community and stakeholders in medical science are watching closely for advancements that could change the approach to cannabis use disorder. For further details about PleoPharma, you can visit their official website at PleoPharma.com.